Viridian Therapeutics, Inc.\DE (VRDN) Operating cash flow 2016–2025
Viridian Therapeutics, Inc.\DE (VRDN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$276.4MFY2025 · since FY2016: -$14.8M → -$276.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$276.4M | -19.0% |
| FY2024 | -$232.3M | -26.1% |
| FY2023 | -$184.2M | -96.3% |
| FY2022 | -$93.8M | -71.9% |
| FY2021 | -$54.6M | -83.3% |
| FY2020 | -$29.8M | +17.4% |
| FY2019 | -$36.1M | -34.3% |
| FY2018 | -$26.8M | +4.7% |
| FY2017 | -$28.2M | -90.9% |
| FY2016 | -$14.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice